S1

# **Supporting Information**

# Synthesis, crystal structure, DNA interaction and *in vitro* anticancer activity of a Cu(II) complex of purpurin: Dual poison for human DNA topoisomerase I and II

Piyal Das<sup>a</sup>, Chetan Kumar Jain<sup>b,d</sup>, Sanjoy K. Dey<sup>c</sup>, Rajat Saha<sup>c</sup>, Abhishek Dutta Chowdhury<sup>a</sup>, Susanta Roychoudhury<sup>b</sup>, Sanjay Kumar<sup>c</sup>, Hemanta Kumar Majumder<sup>d</sup> Saurabh Das<sup>\*a</sup>

## Supplementary contents

## **Preparation of solutions**

LH<sub>3</sub> of ~96% purity was purchased from Sigma-Aldrich and purified by re-crystallization from ethanol-water mixtures. The compound being photosensitive was stored in the dark. Solution of LH<sub>3</sub> was prepared in ethanol (1 mM) just before use. Aqueous Tris buffer was used to maintain pH. Sodium nitrate (AR) and sodium chloride (AR) was used for maintaining ionic strength for studies in solution. Triple distilled water was used in all experiments. Calf thymus DNA, purchased from Sigma-Aldrich was dissolved in triple distilled water. Concentration of DNA solution (in terms of nucleotide) was determined from the absorbance at 260 nm taking molar extinction coefficient as  $6,600 \text{ M}^{-1} \text{ cm}^{-1}$ . Absorbance at 280 nm was also recorded and the ratio  $A_{260}/A_{280}$  was calculated. The ratio being  $1.8 < A_{260}/A_{280} > 1.9$ , indicated the DNA that was used was sufficiently free of protein. Quality of CT DNA was also verified from the CD spectra at 260 nm using a CD spectropolarimeter, J815, JASCO [1]. Proton dissociation of LH<sub>3</sub> (50 µM) in the presence of 25 µM aqueous Cu(NO<sub>3</sub>)<sub>2</sub>was determined with the help of a pH-metric titration [2,3].

### Determination of stoichiometry of the Cu(II) complex of LH<sub>3</sub> at different pH

Stoichiometry was determined by mole-ratio method keeping either concentration of Cu(II) or LH<sub>3</sub> constant and varying the other component. Change in absorbance was measured at 513 nm and plotted against ratio of LH<sub>3</sub> to Cu(II) [Fig. S1(a)] or Cu(II) to LH<sub>3</sub> [Fig. S1(b)]. Straight lines were obtained intersection of which determines stoichiometry of the complex. Fig. S1(a) & S1(b) suggest formation of a 1:2 metal-ligand complex at neutral pH. However, in more alkaline conditions, pH > 8.54 [Fig. S1(c)], both 1:1 and 1:2 complexes were formed [2].



**Figure S1.** (a) and (b): Mole-ratio plot showing the interaction of  $Cu^{(II)}$  with LH<sub>3</sub> in solution at neutral pH; (c): Mole-ratio plot showing the interaction of  $Cu^{(II)}$  with LH<sub>3</sub> in solution at pH 8.54. (d) Spectrophotometric titration of LH<sub>3</sub> in presence of Cu(II) in the ratio 2:1, shown by the variation of absorbance at 513 nm; [NaNO<sub>3</sub>] = 10 mM, T = 298 K.

## Determination of stability constant of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> in solution:

Formation constant for the complex was determined with the help of a spectrophotometric titration where Cu(II) and LH<sub>3</sub> were taken in the ratio 1:2. The change in absorbance at 513 nm over the pH range 2.5 to 11.0 showed a gradual increase with a corresponding increase in pH that became constant beyond pH 10. In the pH range 4.5 to 7, a proton from the –OH group at C<sub>1</sub> got ionized (Eq. 1) [3].



The deprotonated LH<sub>3</sub> reacted with Cu(II) resulting in equilibrium 2.

$$Cu^{2+} + 2LH_3 \rightleftharpoons Cu(LH_2)_2 + 2H^+$$
(2)

The change in absorbance  $(A_{obs})$  at 513 nm could be described as:

$$A_{obs} = A_1 / (1 + 10 \ {}^{pH-pK}_1 + 10 \ {}^{pH-pK}_2) + A_2 / (1 + 10 \ {}^{pK}_1 - {}^{pH} + 10 \ {}^{pH-pK}_2) + A_3 / (1 + 10 \ {}^{pK}_1 - {}^{pH} + 10 \ {}^{pK}_2 - {}^{pH})$$
(3)

 $A_1$ ,  $A_2$  and  $A_3$  refer to the absorbance of LH<sub>2</sub>H<sup>\*</sup>, LH<sup>\*</sup>H<sup>-</sup> and LH<sup>2-</sup> respectively in the presence of Cu<sup>(II)</sup>. Fitting the experimental data according to equation (3) (Fig. 1Sd), the value for pK was  $5.99 \pm 0.20$  and  $8.97 \pm 0.15$  respectively. Using this value and equations 4-7 stability constant of the complex was determined in solution [2-4].

$$\beta^* = \frac{\left[Cu(LH_2)_2\right]\left[H^+\right]^2}{\left[Cu^{2+1}\right]\left[LH_3\right]^2}$$
(4)

$$Cu^{2+} + 2LH_2^{-} \rightleftharpoons Cu(LH_2)_2 \tag{5}$$

$$\beta = \frac{[Cu(LH_2)_2]}{[Cu^{2+}][LH_2^{-}]^2}$$
(6)  
$$\beta = \frac{\beta^*}{K^2}$$
(7)

K refers to the equilibrium constant for the dissociation of phenolic-OH of LH<sub>3</sub> on C<sub>1</sub> [1]. The value for the formation constant ( $\beta$ ) was determined from Eq. 7 and found to be 4.88 × 10<sup>15</sup> comparable to reported stability constants of Cu(II) with doxorubicin [(4.6 ± 1.1) × 10<sup>16</sup>] and sodium 1,4-dihydroxy-9,10-anthraquinone-2-sulphonate [9.64 × 10<sup>16</sup>] [2,4].

The initial structural model for Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> that was used to arrive at the structure of the complex from PXRD data.



Expected/probable structure of Cu(II) complex of LH<sub>3</sub> or *trans*-[Cu(II)-(LH<sub>2</sub>)<sub>2</sub>]



Ligand: 1,2,4-trihydroxy-9,10-anthraquinone or purpurin or LH<sub>3</sub>

# TDDFT of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>:

**Table 1S.** MO composition of  $Cu^{(II)}$ - $(LH_2)_2$  complex in triplet (S=1) ground state calculated byDFT/(U)B3LYP method in acetonitrile.

α-spin					
МО	Energy (eV)	Composition (%)			
		Cu	LH <sub>3</sub>		
LUMO+19	2.982	3	97		
LUMO+18	2.673	77	23		
LUMO+17	2.566	13	87		
LUMO+16	2.285	5	95		
LUMO+15	0.922	0	100		
LUMO+14	0.876	1	99		
LUMO+13	0.7	12	88		
LUMO+12	0.659	13	87		
LUMO+11	0.501	112	-12		
LUMO+10	0.152	75	25		
LUMO+9	0.103	84	16		
LUMO+8	-0.178	106	-6		
LUMO+7	-0.647	1	99		
LUMO+6	-0.69	2	98		
LUMO+5	-1.29	0	100		
LUMO+4	-1.336	1	99		
LUMO+3	-2.209	0	100		
LUMO+2	-2.256	0	100		
LUMO+1	-3.921	0	100		
LUMO	-3.987	0	100		
SOMO	-6.35	1	99		
HOMO-1	-6.542	1	99		
HOMO-2	-7.419	1	99		
HOMO-3	-7.439	0	100		
HOMO-4	-7.452	1	99		
HOMO-5	-7.533	0	100		
HOMO-6	-7.746	12	88		
HOMO-7	-7.787	0	100		
HOMO-8	-7.794	2	98		
HOMO-9	-8.023	1	99		
HOMO-10	-8.056	0	100		
HOMO-11	-8.608	4	96		
HOMO-12	-8.686	1	99		

HOMO-13	-8.855	2	98		
HOMO-14	-9.378	19	81		
HOMO-15	-9.561	1	99		
HOMO-16	-9.929	3	97		
HOMO-17	-10.017	9	91		
HOMO-18	-10.08	2	98		
HOMO-19	-10.118	3	97		
β-spin					
ΜΟ	Energy (eV)	Composition			
		Cu	LH <sub>3</sub>		
LUMO+19	2.663	72	28		
LUMO+18	2.583	18	82		
LUMO+17	2.306	5	95		
LUMO+16	0.924	0	100		
LUMO+15	0.877	1	99		
LUMO+14	0.704	14	86		
LUMO+13	0.663	13	87		
LUMO+12	0.503	112	-12		
LUMO+11	0.145	74	26		
LUMO+10	0.11	84	16		
LUMO+9	-0.112	104	-4		
LUMO+8	-0.642	1	99		
LUMO+7	-0.687	2	98		
LUMO+6	-1.289	0	100		
LUMO+5	-1.334	1	99		
LUMO+4	-2.207	0	100		
LUMO+3	-2.254	0	100		
LUMO+2	-3.899	18	82		
LUMO+1	-3.911	45	55		
LUMO	-3.967	1	99		
НОМО	-6.318	1	99		
HOMO-1	-6.525	1	99		
HOMO-2	-7.427	0	100		
HOMO-3	-7.439	0	100		
HOMO-4	-7.465	0	100		
HOMO-5	-7.539	0	100		
HOMO-6	-7.791	0	100		
HOMO-7	-7.792	0	100		
HOMO-8	-7.991	2	98		
HOMO-9	-8.04	0	100		
HOMO-10	-8.342	1	99		
HOMO-11	-8.549	5	95		
HOMO-12	-8.826	2	98		
HOMO-13	-9.019	22	78		

HOMO-14	-9.302	26	74
HOMO-15	-9.344	2	98
HOMO-16	-9.858	18	82
HOMO-17	-9.894	18	82
HOMO-18	-10.037	17	83
HOMO-19	-10.061	1	99

# IR, EPR and Mass of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>

IR spectrum was recorded on a Perkin Elmer RX-1 spectrophotometer. Mass spectrum was recorded on Micromass Q-Tof micro<sup>™</sup>, Waters Corporation. Elemental analysis was carried out on a Perkin Elmer 2400 Series-II CHN analyzer. EPR spectrum was recorded in solid state in JEOL JES-FA 200 ESR spectrophotometer.

## Analysis of the IR spectra

IR spectrum of LH<sub>3</sub> showed a peak at 3383 cm<sup>-1</sup> characteristic of O–H stretching (Fig. S2) while the complex showed a broad band at 3436 cm<sup>-1</sup> (Fig. S3). A complete absence of the peak at this region was however not observed for Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> since each LH<sub>2</sub><sup>-</sup> bound to Cu(II) had two other -OH groups in the molecule. IR spectrum of LH<sub>3</sub> (Fig. S2) had a characteristic carbonyl stretching at 1670 cm<sup>-1</sup> that was absent in Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> (Fig. S3) indicating the carbonyl oxygen was involved in binding the metal ion.



Figure S2. IR spectrum of LH<sub>3</sub>.



Figure S3. IR spectrum of  $Cu^{(II)}$ - $(LH_2)_2$  complex.

#### Analysis of Mass spectrum

The mass spectrum of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> (Fig. S4) matched the crystal structure. The molecular ion peak was detected bound to sodium at m/z = 629.98 ( $^{63}$ Cu) and 632.0 ( $^{65}$ Cu) respectively. The most intense signals were at m/z = 354.27 (calculated m/z = 354.2) and 356.29 (calculated m/z = 356.2) respectively corresponding to a fragment that contained a Cu atom bound to one LH<sub>3</sub> and two molecules of water. The isotopic distribution for Cu tallied appreciably with the intensity of the two peaks (m/z 354.27 and 356.29). Dissociation of a molecule of water from this species (m/z = 354.2 or 356.2) along with loss of one or more hydrogens generated a peak having m/z = 337.2. Loss of the second water molecule resulted in the fragment (m/z = 311.2). A peak at m/z = 301.2 corresponds to a fragment where a Cu atom was bound to LH<sub>3</sub> from which a phenolic – OH departed.



Figure S4. Mass spectrum of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>

EPR:

The EPR spectrum (Fig. S5) of  $Cu^{(II)}$ -(LH<sub>2</sub>)<sub>2</sub> provides a *g*-value = 2.08 that was consistent with CuL<sub>2</sub> type copper complexes of 1-hydroxy-9,10-anthraquinone, 1,8-dihydroxy-9,10-anthraquinone [5] and of the anticancer drug adriamycin [6,7]. Spin density analysis by DFT study (Fig. 1h) revealed a mixed metal-ligand behavior of the paramagnetic complex as was experimentally found in the EPR spectrum. EPR spectral features of Cu<sup>2+</sup> complexes of several hydroxy-9,10-anthraquinones were found to be similar to Cu<sup>2+</sup>-ADM [5-7] that was assigned to species having tetragonal coordination structure indicating both systems form similar coordination complexes with Cu<sup>2+</sup>. Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub> shows signals in the field strength 250 to 350 mT attributed to CuL<sub>2</sub> type complexes mentioned above.



Figure S5. Low temperature (77 K) solid state ESR spectra of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>

### CT DNA interaction of LH<sub>3</sub> and Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>: UV-Vis study

Binding of the compounds with CT DNA was studied considering the following equilibrium on the interaction of small molecules with DNA.

$$L + DNA \rightleftharpoons L - DNA \qquad \qquad K_d = \frac{[L][DNA]}{[L - DNA]} \tag{8}$$

Equation 8 considered in the reverse direction yields a double reciprocal Equation 9.

$$\frac{1}{\Delta A} = \frac{1}{\Delta A_{max}} + \frac{K_d}{\Delta A_{max}(C_D - C_L)}$$
(9)

The decrease in absorbance ( $\Delta A$ ) on titrating each compound with CT DNA was used to create binding isotherms at different pH [8].  $\Delta A_{max}$  indicates the maximum change in absorbance following interaction of the compounds with CT DNA. C<sub>D</sub> denotes concentration of CT DNA present in any aliquot and C<sub>L</sub> the concentration of the compounds. K<sub>d</sub> and  $\Delta A_{max}$  was evaluated [1,9,10] utilizing equation 9.



**Figure S6.** (a) Binding isotherm of the spectrophotometric study of LH<sub>3</sub>–CT DNA interaction with the corresponding non-linear fit. Inset: Plot of normalized increase in absorbance as a function of the mole-ratio of LH<sub>3</sub> to CT DNA; (b) A Scatchard plot obtained for the interaction of LH<sub>3</sub> with CT DNA based on a titration followed by UV-Vis spectroscopy;  $[LH_3] = 75 \mu M$ , [NaCl] = 120 mM; [Tris buffer] = 15 mM at pH = 7.88; T = 298 K.

Change in absorbance was followed at the  $\lambda_{max}$  of LH<sub>3</sub> at the pH in which experiments were done. In the pH range 6.65 to 8.35, change in absorbance ( $\Delta A$ ) was followed at 513 nm. Fig. S6(a) being a typical plot of  $\Delta A/\Delta A_{max}$  against concentration of DNA fitted by non-linear square fit analysis [1,9,10] (Eq. 10 & 11) to evaluate K<sub>d</sub> at pH 7.8.

$$K_{d} = \frac{\left[C_{L} - \left(\frac{\Delta A}{\Delta A_{max}}\right)C_{L}\right] \left[C_{D} - \left(\frac{\Delta A}{\Delta A_{max}}\right)C_{L}\right]}{\left(\frac{\Delta A}{\Delta A_{max}}\right)C_{L}}$$
(10)  
$$C_{L} \left(\frac{\Delta A}{\Delta A_{max}}\right)^{2} - \left(C_{L} + C_{D} + K_{d}\right) \left(\frac{\Delta A}{\Delta A_{max}}\right) + C_{D} = 0$$
(11)

The plot of  $\Delta A/\Delta A_{max}$  against [DNA]/[LH<sub>3</sub>] [Inset, Fig. S6(a)] at different pH was done to obtain " $n_{b,}$ " the site size of interaction. Overall binding constant (K\*) at each pH was obtained by multiplying  $K_{app}$  with " $n_b$ ".

The Scatchard equation (Eq. 12) [11] was also used to analyze the results obtained from UV-Vis titration of LH<sub>3</sub> with CT DNA. Overall binding constant (K\*) and binding stoichiometry " $n_b$ " was obtained directly [1,2] from Fig. S6(b).

$$r / C_f = K^* (n - r) \tag{12}$$

 $r = C_b/C_D$  where, " $C_b$ " is the concentration of bound LH<sub>3</sub> and " $C_D$ " the concentration of CT DNA. " $C_f$ " refers to concentration of free compound. "K\*" is the intrinsic binding constant or overall binding constant of any molecule binding to a substrate. "n" is the binding stoichiometry in terms of number of bound compound per nucleotide while " $n_b$ ," reciprocal of "n" denotes

binding site size in terms of the number of nucleotide per molecule. K\* values obtained from the Scatchard plot for LH<sub>3</sub> at different pH are summarized in Table 2S. It was observed as pH increased overall binding constant of LH<sub>3</sub> with CT DNA gradually decreased [8].

**Table 2S.** Results of the binding constants of LH<sub>3</sub> with CT DNA with the variation of pH at constant ionic strength of the medium.

pH	Intrinsic binding constant (M <sup>-1</sup> )
6.65	$9.33  imes 10^{4}$
6.88	$6.45 \times 10^{4}$
7.16	$4.84 \times 10^{4}$
7.40	$4.51 \times 10^{4}$
7.88	2.95 ×10 <sup>4</sup>
8.35	2.56 ×10 <sup>4</sup>

CT DNA interaction of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>: UV-Vis study



**Figure S7.** (a) Double-reciprocal plot of the interaction of  $Cu^{(II)}$ - $(LH_2)_2$  with CT DNA based on a titration followed by UV-Vis spectroscopy (b) Scatchard plot for the interaction of  $Cu^{(II)}$ - $(LH_2)_2$  with CT DNA; (c) Benesi-Hildebrand plot for the interaction of  $Cu^{(II)}$ - $(LH_2)_2$  with CT DNA;  $[Cu^{(II)}$ - $(LH_2)_2] = 75 \mu$ M, [NaCl] = 120 mM; [Tris] = 15 mM of pH = 7.42; T = 298 K.

CT DNA interaction of Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>: fluorescence study



**Figure S8.** (a) Double-reciprocal plot for the interaction of  $Cu^{(II)}-(LH_2)_2$  with CT DNA studied with the help of fluorescence spectroscopy. (b) Scatchard plot for the interaction of  $Cu^{(II)}-(LH_2)_2$  with CT DNA;  $[Cu^{(II)}-(LH_2)_2] = 75 \mu$ M, [NaCl] = 120 mM; [Tris] = 15 mM of pH = 7.42; T = 298 K.

#### Kinetoplast DNA (kDNA) decatenation assay for topoismerase II enzyme

kDNA release assay for recombinant human topoisomerase II was performed in the presence or absence of the respective compounds by briefly incubating 100 ng of kDNA with 50 fmol of the enzyme in the reaction buffer supplied by the manufacturer (TopoGEN Inc.). DOX was used as the positive control drug that inhibits topoisomerase II by stabilizing covalent topoisomerase II-DNA complexes. DMSO concentration was maintained at 1% (vehicle control). Reactions were incubated at 37°C for 30 minutes, loaded on 1% agarose gel with 0.5 µg/ml ethidium bromide and electrophoresis was done at 80 volts for 3 hours. On completion of electrophoresis, gels were viewed by Gel Doc 2000 (BioRad) under UV illumination. kDNA decatenation was assessed by monitoring the released kDNA minicircles in the gel.



Figure S9. Kinetoplast DNA (kDNA) decatenation assay for topoismerase II enzyme. Lane 1:100 ng kDNA, lane 2:100 ng kDNA with 50 fmol topoisomerase II enzyme, lane 3: same as lane 2 but with 10 μM DOX, lane 4: same as lane 2 but with 20 μM LH<sub>3</sub>, lane 5: same as lane 2 but with 20 μM Cu<sup>(II)</sup>-(LH<sub>2</sub>)<sub>2</sub>. All reactions were incubated at 37 °C for 30 minutes and stopped with 0.5% SDS and analysed by agarose gel electrophoresis.

#### **References:**

- P. Das, P. S. Guin, P. C. Mandal, M. Paul, S. Paul, S. Das, J. Phy.Org. Chem. 24 (2011) 774.
- [2] P. S. Guin, S. Das, P. C. Mandal, J. Inorg. Biochem. 103 (2009) 1702.
- [3] S. Das, A. Saha, P. C. Mandal, Talanta 43 (1996) 95.
- [4] H. Beraldo, A. G. Suillerot, L. Tosi, Inorg. Chem. 22 (1983) 4117.

- [6] M. Tachibana, M. Iwaizumi, S. Tero-Kobuta, J. Inorg. Biochem. 30 (1987) 133.
- [7] F. Morazzoni, A. Gervasini, Inorg. Chim. Acta. 136 (1987) 111.
- [8] S. Mukherjee, P. Das, S. Das, J. Phy.Org. Chem. 25 (2012) 385.
- [9] S. Roy, R. Banerjee, M. Sarkar, J. Inorg. Biochem. 100 (2006) 1320.
- [10] S. Chakraborti, B. Bhattacharyya, D. Dasgupta, J. Phys. Chem. B 106 (2002) 6947.
- [11] G. Scatchard, Ann. N. Y. Acad. Sci. 51 (1949) 660.